The effects of a 5-lipoxygenase inhibitor on antigen-induced mediator release, late-phase bronchoconstriction and cellular infiltrates in primates.
Inhaled BI-L-239 significantly inhibited i-LTC4 generation, late-phase bronchoconstriction and the influx of neutrophils into the lungs. We conclude that leukotriene generation and release within the lungs, following allergen exposure, in part mediate altered lung function and contribute to the development of airway inflammation. As such, treatment with a selective 5-lipoxygenase inhibitor may aid in the treatment of bronchial asthma and other allergic diseases.
Gundel
R H
RH
Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT 06877.
Torcellini
C A
CA
Clarke
C C
CC
Desai
S
S
Lazer
E S
ES
Wegner
C D
CD
D000281:Administration, Intranasal; D000336:Aerosols; D000818:Animals; D000941:Antigens / Q000494:pharmacology*; D001507:Beclomethasone / Q000494:pharmacology; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D016084:Bronchoconstriction / Q000187:drug effects*; D003907:Dexamethasone / Q000494:pharmacology; D015289:Leukotrienes / Q000096:biosynthesis; D016859:Lipoxygenase Inhibitors; D008252:Macaca fascicularis / Q000378:metabolism*; D008297:Male; D010636:Phenols / Q000494:pharmacology*; D015230:Prostaglandin D2 / Q000032:analysis; D013189:SRS-A / Q000032:analysis
D000336:Aerosols; D000941:Antigens; D015289:Leukotrienes; D016859:Lipoxygenase Inhibitors; D010636:Phenols; D013189:SRS-A; C067524:enofelast; D003907:Dexamethasone; D001507:Beclomethasone; D015230:Prostaglandin D2